Table 4.
Mean Full Field Hill of Vision (VTOT) Stratified by Clinical Diagnosis and Baseline Characteristicsa
| Characteristic | Overall | Clinical Diagnosis | ||||
|---|---|---|---|---|---|---|
| USH2 | ARRP | |||||
|
| ||||||
| N=126 | VTOT Mean (SD) | N=80 | VTOT Mean (SD) | N=46 | VTOT Mean (SD) | |
|
| ||||||
| Gender | ||||||
| Female | 68 | 27.4 (22.3) | 44 | 22.9 (20.8) | 24 | 35.5 (23.1) |
| Male | 58 | 28.4 (25.4) | 36 | 21.9 (22.6) | 22 | 38.9 (26.7) |
| Race/Ethnicity | ||||||
| White | 112 | 28.2 (23.7) | 70 | 21.9 (20.8) | 42 | 38.6 (24.8) |
| Hispanic | 9 | 26.4 (24.4) | 7 | 27.6 (25.6) | 2 | 22.4 (28.1) |
| Asian | 5 | 21.8 (27.1) | 3 | 23.0 (35.4) | 2 | 20.0 (20.1) |
| Enrollment area | ||||||
| United States | 83 | 25.7 (23.0) | 50 | 21.1 (21.2) | 33 | 32.5 (24.1) |
| Europe/UK | 43 | 32.0 (24.8) | 30 | 24.7 (22.1) | 13 | 48.8 (23.1) |
| Age at enrollment, yrs b | ||||||
| <35 | 44 | 35.7 (23.0) | 36 | 33.1 (20.0) | 8 | 47.6 (32.5) |
| 35–45 | 43 | 23.9 (22.4) | 25 | 18.3 (20.1) | 18 | 31.8 (23.6) |
| >= 45 | 39 | 23.1 (24.2) | 19 | 7.8 (15.3) | 20 | 37.8 (22.0) |
| Duration of Disease, yrs c | ||||||
| <10 | 36 | 40.5 (22.6) | 20 | 34.3 (20.0) | 16 | 48.2 (23.9) |
| [10,20) | 46 | 28.5 (21.9) | 25 | 28.7 (23.5) | 21 | 28.3 (20.4) |
| >=20 | 43 | 15.0 (18.2) | 35 | 11.2 (14.8) | 8 | 31.5 (23.4) |
| Smoking status | ||||||
| Yes | 33 | 31.2 (24.7) | 20 | 25.9 (24.2) | 13 | 39.3 (24.2) |
| No | 93 | 26.6 (23.4) | 60 | 21.3 (20.6) | 33 | 36.3 (25.2) |
| Current use of dietary supplements | ||||||
| None | 53 | 32.3 (23.9) | 41 | 25.6 (20.5) | 12 | 55.0 (20.7) |
| Vitamin A only | 11 | 14.9 (16.0) | 5 | 9.5 (12.7) | 6 | 19.5 (18.1) |
| DHA only | 5 | 15.8 (13.1) | 3 | 17.0 (15.4) | 2 | 13.9 (14.3) |
| Lutein only | 8 | 32.2 (23.5) | 5 | 24.4 (21.5) | 3 | 45.3 (24.4) |
| Combination | 49 | 26.4 (24.9) | 26 | 20.2 (24.6) | 23 | 33.4 (23.7) |
Static perimetry results were graded by a reading center. Results are based on the average of 3 fields when 3 tests were performed (primary cohort); otherwise they are based on the 1 test performed (secondary cohort). Static perimetry data is not included for 1 participant in the ARRP group (participant was not tested). Factors are presented categorically to show the data but were analyzed using a continuous version of the factor in the model. None of the other factors in the table were significantly associated with VTOT once disease duration, age of enrollment and clinical diagnosis were accounted for (P-value not shown).
28 participants were not permitted to report date of birth due to regulatory restrictions. Therefore, only year of birth and categorical age was reported. For those participants, July 1st with the reported birth year was imputed as birth date to calculate continuous age
1 participant in the ARRP group was missing age of onset (a participant-reported field based on their awareness of visual symptoms) and duration of disease (computed based on age of onset and date of enrollment)